the Boiron laboratory announces its intention to eliminate 145 positions

The Boiron laboratory, shaken by the delisting of homeopathy in France, announced a new restructuring plan on Thursday, leading to the possible elimination of 145 positions in France. The group suffered from the gradual dereimbursement of homeopathic medicines by Social Security, before recovering thanks to savings following a reorganization plan. The group had already cut more than 500 positions in 2021 after the decision to completely dereimburse homeopathy taken by the French government.

A new reorganization project in France for the homeopathy activity has been “submitted today to staff representatives” and to the board of directors, according to a press release from Boiron. “This project would result in the elimination of 145 positions in France, including 117 filled and 28 vacant”adds the press release. In detail, four distribution establishments in Clermont-Ferrand, Dijon, Reims and Sophia-Antipolis will be closed, leading to the elimination of 73 positions. In addition, the elimination of 40 positions is planned within the distribution establishments of Bordeaux, Marseille, Nancy, Nantes, Rennes, Toulouse, Tours, as well as 32 positions in medical examination.

Due to the delisting of homeopathy, “volumes have been divided by 3 in 5 years, signifying a drop of more than 100 million euros in turnover”argues the group. The laboratory offers “a set of support measures aimed in particular at favoring voluntary departures and age measurements”or specific schemes intended for employees close to retirement. Homeopathy, previously reimbursed at 65%, saw its reimbursement rate gradually decrease before being completely excluded.